Grove Biopharma
About Grove Biopharma
Grove Biopharma is engineering synthetic biologics that can access and modulate previously “undruggable” intracellular targets, offering promising treatment avenues for neurodegenerative diseases, cancer, and beyond.
News: Grove Biopharma Closes $30 Million Series A Financing to Advance Bionic Biologics, a New Therapeutic Modality (April 2025)
Our Interest
Walder Ventures’ focus on science innovation is driven by Joseph Walder, M.D., Ph.D., who spent his career developing breakthrough technologies in academic research before founding a biotech company, Integrated DNA Technologies, now part of the Danaher life sciences platform, that produces synthetic DNA and RNA for life sciences research and industry.